Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Key Highlights
- ➤Black Diamond announces three investor conference presentations scheduled November 19 through December 2, 2026
- ➤Silevertinib Phase 3 trial planned for Q2 2027 in 1L EGFRm NSCLC patients
- ➤Over 200 patients with EGFRm NSCLC or EGFR-altered GBM treated with silevertinib
- ➤Silevertinib targets classical and more than 50 non-classical EGFR mutations in NSCLC
Expert Statements
Mark Velleca, President and Chief Executive Officer of Black Diamond Therapeutics
“Mark Velleca, M.D., Ph.D.”
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: * Jefferies Global Healthcare Conference in London presentation at 8:30am GMT / 3:30am ET on Thursday, November 19, 2026 * 9th Annual Evercore ISI Healthcare Conference presentation at 10:25am ET on Tuesday, December 1, 2026 * Piper Sandler 38th Annual Healthcare Conference presentation at 12:00pm ET on Wednesday, December 2, 2026 Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.
Get started
Create a free account to read the full story.